Skip to content

Near-infrared Fluorescence Imaging as a Supportive Tool for Localisation of Deep Infiltrating Endometriosis During Laparoscopy

Indocyanine Green and Near-Infrared Vision for Detection of Endometriosis (GRE-Endo Trial)

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03332004
Enrollment
27
Registered
2017-11-06
Start date
2016-01-04
Completion date
2017-02-16
Last updated
2017-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis Outside Pelvis, Pelvic Endometriosis

Keywords

Indocyanine Green, Deep Infiltrating Endometriosis, Near-Infrared Vision, Occult endometriosis, Invisible endometriosis

Brief summary

The aim of the study is to establish a new and more accurate method to visualize the peritoneal changes caused by endometriosis using Indocyanine Green mediated fluorescence imaging. The hypothesis is that Indocyanine Green, a fluorescent dye that has wide applications throughout medicine in identifying vascularity of tissues and neovascularization, could facilitate the localization and excision of endometriotic lesions exploiting the hypervascularization due to the chronic inflammation

Detailed description

Patients were recruited within the clinical routine after indication for laparoscopy under consideration of the inclusion and exclusion criteria. The first abdominal and pelvi's inspection was made using direct laparoscope visualization under white light conditions. All areas suspected of peritoneal endometriosis were classified as white, black and red lesions and recorded together with their anatomic location in the surgical record for the purposes of subsequent extirpation. After the first visual inspection the patient was administered with 0.05 - 0.25 mg /(kg BW) Indocyanine Green intravenously. The Indocyanine Green imaging mode of the Olympus Indocyanine Green Imaging System was activated and suspected areas in Indocyanine Green imaging mode were recorded with their corresponding appearance in white light mode. If suspected areas were visible either in white light or Indocyanine Green imaging mode, specific sample has been taken from these areas. In addition control biopsy specimens from inconspicuous peritoneum has been taken.

Interventions

DRUGIndocyanine Green

0.25 mg /(kg BW) Indocyanine Green PULSION® - PULSION Medical Systems were administered intravenously

Sponsors

Catholic University of the Sacred Heart
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

In the selected patients, after a first white light visual inspection, 0.25 mg/(kg BW) ICG were injected intravenously. After 5 to 30 minutes a second inspection of the abdomen and pelvis in Near Infrared vision was made. All the visualized lesions were carefully described pre and post the Indocyanine Green injection, removed and listed

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Suspected endometriosis with necessity for laparoscopic confirmation and resection * Regular menstrual cycles

Exclusion criteria

* Patients younger than 18 years and older than 50 years at time of operation * Subject with previous history of adverse reaction or allergy to Indocyanine Green, iodine, shellfish or iodine dyes * Documented allergy to sulfur containing compounds * History of allergic reactions attributed to compounds of similar chemical or biologic composition to Indocyanine Green * Subject has significant liver disease, cirrhosis or liver insufficiency with abnormal liver function tests (Total bilirubin increased by factor 1.5 than normal and/or serum glutamic oxaloacetic transaminase increased by factor 2 than normal) * Subject has uremia, serum creatinine (\> 2.0 mg/dl) * Subject has severe coronary heart disease (instable angina pectoris) * Pregnant or breast-feeding women * Subject actively participating in another drug, biologic and/or device protocol * The presence of medical conditions contraindicating general anesthesia or standard surgical approaches * Subject has any medical condition, which in the judgment of the Investigator and/or designee makes the subject a poor candidate for the investigational procedure

Design outcomes

Primary

MeasureTime frameDescription
Detection of endometriotic lesionsIntraoperativeOptical qualitative assessment through the visual evaluation of a single expert surgeon (presence / absence of fluorescence, due to the injection of the Indocyanine Green and the use of the Near Infrared vision, at the level the of suspected endometriotic lesions)

Secondary

MeasureTime frameDescription
Localization of occult endometriotic lesionIntraoperativeTo detect occult endometriotic lesions, thanks to the fluorescence of the Indocyanine Green, that would remain otherwise not visible to the surgeon eye
Operatory TimeIntraoperativeTo assess if the use of Indocyanine Green cause a significant increase of the operatory time
ComplicationsFrom operatory room up to 3 daysTo assess if the use of Indocyanine Green increase the percentage of intra and post-operative complications
Side effectsFrom operatory room up to 3 daysEvaluation of possible side effects related to the use of Indocyanine Green as a fluorescent endometriosis' marker

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026